Rockefeller Capital Management L.P. Purchases 1,864 Shares of Hims & Hers Health, Inc. (NYSE:HIMS)

Rockefeller Capital Management L.P. grew its holdings in shares of Hims & Hers Health, Inc. (NYSE:HIMS) by 5.8% in the 3rd quarter, Holdings Channel.com reports. The firm owned 33,775 shares of the company’s stock after purchasing an additional 1,864 shares during the quarter. Rockefeller Capital Management L.P.’s holdings in Hims & Hers Health were worth $622,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also recently made changes to their positions in HIMS. Nisa Investment Advisors LLC grew its position in Hims & Hers Health by 679.2% during the second quarter. Nisa Investment Advisors LLC now owns 1,839 shares of the company’s stock valued at $37,000 after buying an additional 1,603 shares during the period. Quest Partners LLC grew its position in shares of Hims & Hers Health by 5,944.1% during the 2nd quarter. Quest Partners LLC now owns 3,566 shares of the company’s stock valued at $72,000 after acquiring an additional 3,507 shares during the period. Van ECK Associates Corp bought a new stake in shares of Hims & Hers Health during the 2nd quarter valued at $111,000. CWM LLC increased its stake in shares of Hims & Hers Health by 21.4% in the 3rd quarter. CWM LLC now owns 5,982 shares of the company’s stock worth $110,000 after purchasing an additional 1,054 shares in the last quarter. Finally, Amalgamated Bank raised its holdings in Hims & Hers Health by 55.9% in the 2nd quarter. Amalgamated Bank now owns 6,566 shares of the company’s stock worth $133,000 after purchasing an additional 2,354 shares during the period. Institutional investors own 63.52% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have issued reports on HIMS shares. Piper Sandler reissued a “neutral” rating and set a $21.00 price target (up previously from $18.00) on shares of Hims & Hers Health in a report on Tuesday, November 5th. Needham & Company LLC assumed coverage on Hims & Hers Health in a research note on Thursday, August 22nd. They set a “buy” rating and a $24.00 price objective for the company. TD Cowen restated a “buy” rating and set a $28.00 target price on shares of Hims & Hers Health in a research note on Wednesday, November 20th. Canaccord Genuity Group lifted their price target on shares of Hims & Hers Health from $28.00 to $38.00 and gave the company a “buy” rating in a report on Monday, December 2nd. Finally, Bank of America cut shares of Hims & Hers Health from a “buy” rating to an “underperform” rating and reduced their price objective for the stock from $32.00 to $18.00 in a research note on Thursday, November 14th. One research analyst has rated the stock with a sell rating, eight have given a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $21.43.

Hims & Hers Health Stock Down 4.7 %

Shares of Hims & Hers Health stock opened at $32.62 on Tuesday. The firm has a market cap of $7.13 billion, a price-to-earnings ratio of 74.13 and a beta of 1.24. Hims & Hers Health, Inc. has a twelve month low of $8.09 and a twelve month high of $35.02. The business has a 50-day moving average price of $23.82 and a 200-day moving average price of $20.64.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings results on Monday, November 4th. The company reported $0.32 earnings per share for the quarter, beating the consensus estimate of $0.06 by $0.26. The business had revenue of $401.56 million during the quarter, compared to analysts’ expectations of $382.20 million. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The firm’s revenue for the quarter was up 77.1% compared to the same quarter last year. During the same quarter last year, the business posted ($0.04) EPS. On average, equities analysts expect that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CFO Oluyemi Okupe sold 12,651 shares of the stock in a transaction dated Friday, September 20th. The shares were sold at an average price of $16.79, for a total value of $212,410.29. Following the completion of the transaction, the chief financial officer now owns 211,000 shares of the company’s stock, valued at approximately $3,542,690. This trade represents a 5.66 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Andrew Dudum sold 45,767 shares of the business’s stock in a transaction that occurred on Friday, September 20th. The stock was sold at an average price of $16.33, for a total value of $747,375.11. Following the sale, the chief executive officer now directly owns 67,015 shares in the company, valued at $1,094,354.95. The trade was a 40.58 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 974,495 shares of company stock worth $22,548,139. Insiders own 17.71% of the company’s stock.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.